Login / Signup

In vitro and in vivo investigation of the novel Dex-bHb as oxygen carriers.

Jun ZhangYing WangShan ZhangGuo-Xing YouPeng-Long LiQuan WangWei-Li YuTao HuHong ZhouLian Zhao
Published in: Artificial cells, nanomedicine, and biotechnology (2019)
The development of hemoglobin-based oxygen carriers (HBOCs) is a persistent and urgent need in biomedicine. As a potential HBOCs, Dextran-hemoglobin (Dex-bHb) has been developed over the past years. The novel Dex-bHb, whose thiol group of Cys-93(β) was reversibly protected, was produced and the characteristics were evaluated in our previous study. Herein, blood compatibility was characterized in terms of the red blood cell aggregation and hemolysis rate in vitro, and Dex-bHb showed no obvious effects. After intravenous administration of Dex-bHb to golden Syrian hamsters with hemorrhages shock, it showed mean arterial pressure recovery, blood flow increase and the organ protection from serious hemorrhage injury. Consequently, Dex-bHb is hopeful to be a safe and available blood substitute.
Keyphrases
  • red blood cell
  • blood flow
  • risk assessment